David Dongliang Ge, J Cancer Sci Ther 2017, 9:10 (Suppl)
DOI: 10.4172/1948-5956-C1-113

David Dongliang Ge

Apostle Inc, USA

Genomic approaches in modern biotechnology- From discovery, translation to implementation

The biotechnology industry has quickly entered an era when fast evolving genome technologies, historical precision medicine initiatives, and disruptive bioinformatics and artificial intelligence techniques synergistically start to provide pivotal and strategic support for new drug and diagnostics development. Unprecedented amount of data is being generated to help discover and develop new generations of medications. Using real-world examples, this presentation will cover several of the most important bioinformatics considerations in this strategy. How do we efficiently manage the massive amount of data at different levels of precision to ensure a seamless data flow? How do we annotate and present these data to make it more comprehensible and deliverable? How do we design and execute the new clinical trials more efficiently and improve the success rate? Where are we and where are we going in this new precision medicine era?.

Biography

David Dongliang Ge is the CEO and President of Apostle Inc., a Silicon-Valley-based Biotechnology Company developing a novel AI-enabled Nano Diagnostics (AID) Technology for early cancer detection. Previously, he was the President of BioSciKin Co. and Simcere Diagnostics Co., two global biotechnology companies headquartered in Nanjing, China. Between 2011 and 2016, he was the Director of Bioinformatics at Gilead Sciences, where he founded and provided Leadership to the Bioinformatics group.

dge@apostlebio.com

Notes: